foxo4-dri senolytic animal model 2023 2024 Senolytic therapeutics: An emerging treatment
Senolytic therapeutics: An emerging treatment modality for osteoarthritis ScienceDirect The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI part 1 , #peptide #molecule #research #health #information Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine
Pay in 4 interest-free payments of $7.19 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


